New data show that Avastin improves overall survival (OS) in women with high risk advanced ovarian cancer - the deadliest gynaecological cancer in the UK2 - offering hope for thousands of women diagnosed with the disease each year.
Phase 3 trial of XTANDI™ in chemotherapy-naive patients meets both co-primary endpoints
10/24/2013
Astellas Pharma Inc. and Medivation, Inc...
New data show that Avastin improves overall survival (OS) in women with high risk advanced ovarian cancer - the deadliest gynaecological cancer in the UK2 - offering hope for thousands of women diagnosed with the disease each year...
New data show that Avastin improves overall survival (OS) in women with high risk advanced ovarian cancer - the deadliest gynaecological cancer in the UK2 - offering hope for thousands of women diagnosed with the disease each year.
Phase 3 trial of XTANDI™ in chemotherapy-naive patients meets both co-primary endpoints
10/24/2013
Astellas Pharma Inc. and Medivation, Inc...
New data show that Avastin improves overall survival (OS) in women with high risk advanced ovarian cancer - the deadliest gynaecological cancer in the UK2 - offering hope for thousands of women diagnosed with the disease each year...
Decision Counseling Program makes prostate cancer treatment decisions easier
10/24/2013
When the pros and cons of prostate cancer treatment are spelled out using an online interactive program developed by Thomas Jefferson University researchers, more patients choose active surveillance over therapy, according to research presented Wednesday at the Society for Medical Decision Making annual meeting in Baltimore, Maryland...
Older AML patients not found to benefit from sequential GO and chemotherapy
10/24/2013
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more...
Study points to possible treatment for brain disorders
10/24/2013
Clemson University scientists are working to determine how neurons are generated, which is vital to providing treatment for neurological disorders like Tuberous Sclerosis Complex (TSC)...
Decision Counseling Program makes prostate cancer treatment decisions easier
10/24/2013
When the pros and cons of prostate cancer treatment are spelled out using an online interactive program developed by Thomas Jefferson University researchers, more patients choose active surveillance over therapy, according to research presented Wednesday at the Society for Medical Decision Making annual meeting in Baltimore, Maryland...